Rethinking the clinical paradigm through Real-World Evidence. Accelerating access for those suffering most in society.
We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines
RWE studies are increasingly recognized as a regulatory pathway which accelerates the time taken to treat patients with urgent and unmet needs. It has been successfully used throughout history for the licensing of medicines, notably the development of Covid-19 vaccines and a number of cancer treatments.
RWE is at the forefront of our regulatory strategy as we seek to deliver on our goal of receiving marketing authorisations for our medicines.
We utilise existing clinical infrastructure, through collaborations with research institutions, hospital centres and government agencies, to deliver and improve patient access to our treatments.
KRN-101, is a potential solution for cancer-related anxiety, a market of over 15 million people with roughly 1 million new sufferers each year. From this initial focus, we will address broader mental health concerns reported to affect over a billion people worldwide.
We are a publicly-traded company listed on the Canadian Securities Exchange (CSE:ABRT) and Frankfurt Stock Exchange (FSE:VB50).
Tens of millions of people are diagnosed with cancer each year, and millions more are living with it. The depression and anxiety that might accompany cancer is self-evident, more commonly known as cancer distress.
Fatigue, worry, insomnia, sadness, fear, and doubts regarding the meaning of one’s life are commonplace with a cancer diagnosis.
Due to the complexities surrounding cancer therapy, too often, patient’s psychological needs are left untreated.
Treating mental health is about helping those who feel helpless. To solve the mental health crisis, suffering must be alleviated on an individual level and at scale.
At Albert Labs, we are held accountable to our promise of treating patients with urgent and unmet mental health needs. The driving force behind our decisions is the wellbeing of the people we serve.
We do so with compassion, collaboration, innovation and responsibility.
Everyone has been impacted by the mental health crisis in someway. We have all seen or experienced the debilitating pressure of mental illness. Our team are no exception and our work is grounded in personal experiences.
We take a patient-first approach and always will. Through our Real-World Evidence studies, access to our therapy for those currently suffering is possible. It is our priority to meet and treat the needs of those we serve.
To meet the global needs of the mental health crisis collaboration is essential. We work with established and leading institutions to deliver our medicine and therapy.
Through Real-World Evidence we work with real people in their home environment and listen to & learn about their needs.
Albert Labs team has a diverse range of skills and expertise including world-renowned researchers, university professors, ex-regulators, ex-big pharma senior management and more. It is our responsibility to ensure our novel therapy is delivered with safety and care. We believe our team is one of the best equipped in the world to do this.
© 2022 Albert Labs. All Rights Reserved
We are a pharmaceutical company leveraging our drug development and clinical research expertise to accelerate the development of highly effective mental health medicines.
If you would like support or more information around making an investment, please contact email@example.com